

Huadong TANG Partner

Intellectual Property | Regulatory and Compliance Dispute Resolution



+86 10 5650 0900-8633

huadong.tang@meritsandtree.com

Beijing

Huadong Tang is a partner at Merits & Tree. Prior to joining M&T, Mr. Tang worked at China Patent Agent (H.K.) Ltd., King & Wood Mallesons for many years, and engaged in the patent examination for a long time in China National Intellectual Property Administration and obtained a senior title.

Mr. Tang has more than ten years of practical experience in technical and legal services and has been deeply involved in the medical and health, providing intellectual property due diligence services for many well-known investment institutions, and handling various patent applications and litigation affairs on behalf of many leading companies in the industry.

Mr. Tang leads a professional team with a compound background in medicine and law, whose main members graduated from famous universities at home and abroad and provides professional and efficient technical and legal support for legal affairs such as intellectual property protection, investment, financing, and M & A, listing and reorganization, dispute resolution and government compliance in the medical and health area.

Mr. Tang specializes in providing operable intellectual property protection schemes from the perspective of clients' commercial purposes, including, but not limited to, patent strategy layout, patent mining, patent application drafting and examination, patent due diligence, patent stability analysis, FTO freedom to implement legal opinions, patent infringement analysis, patent invalidation challenges, patent infringement litigation, trade secret protection, and the construction of intellectual property protection system.

Achievements

Transaction and Due Diligence

- As the intellectual property legal advisor of Keymed Biosciences Inc. (stock code: 2162. HK), provided FTO and intellectual property

legal opinions for its listing on the main board of the Stock Exchange of Hong Kong Ltd. (SEHK);

- As the intellectual property legal advisor of Shukun (Beijing) Network Technology Co., Ltd., provided intellectual property legal opinions for its listing on the main board of the Stock Exchange of Hong Kong Ltd. (SEHK);
- As the intellectual property legal advisor of Shenzhen Edge Medical Co., Ltd., provided FTO and intellectual property legal opinions for its listing on the main board of the Stock Exchange of Hong Kong Ltd. (SEHK);
- Provided full legal services for the intellectual property securitization project, Capital Securities-Hubei Leasing Hubei Province Intangible Assets 1-N Asset Support Special Plan as an intellectual property legal advisor, and provided legal advice for policy formulation and the formulation of standards for selected enterprises from the early stage of legal argumentation to the improvement of the intellectual property secondary licensing transaction model;
- Beijing Heartwarming Biotechnology Research Institute Co., Ltd. entered strategic cooperation with the China Center of Industrial Culture Collection (CICC). M&T, as the intellectual property legal advisor of CICC, provided full legal services for this strategic cooperation;
- GenFleet Therapeutics and Innovent Biologics announced a global strategic collaboration on GFH925 (a small molecule inhibitor of KRAS G12C). The Intellectual Property on Therapeutics Working Group of M&T represented GenFleet Therapeutics to provide the whole process of intellectual property services for this transaction;
- Represented Sequoia Capital in conducting patent due diligence (FTO, etc.) on several pharmaceuticals and medical devices in China, including LP Pharma, Pumice, Biotheus, AccuMedical, Neuracle, Edge Medical, Yuanhua Technology, ET Healthcare, etc.;
- Represented IDG Capital in conducting patent due diligence (FTO, etc.) on Gensciences, Lychix, etc;
- Represented Citic Securities Investment Co., Ltd. in conducting patent due diligence (FTO, etc.) on DAC BIOTECHNOLOGY;
- Represented CITIC Healthcare in conducting patent due diligence (FTO, etc.) on a surgical robot company;
- Represented Shanghai Greenwoods Capital in conducting patent due diligence (FTO, etc.) on Stemirna Therapeutics;
- Represented Dalton Venture in conducting patent due diligence (FTO, etc.) on several medical devices in China, including ShineYo Medical, Chinabridge Medical, etc.;
- Represented Riverhead Capital in conducting patent due diligence (FTO, etc.) on medical device enterprises (biochips) and innovative drug enterprises (small molecule drugs);
- Represented LC Ventures in conducting patent due diligence (FTO, etc.) on Immunophage;
- Represented Legend Capital in conducting patent due diligence (FTO, etc.) on Lychix (biochips);
- Represented Advantech Capital in conducting patent due diligence (FTO, etc.) on a cardiovascular medical device enterprise;
- Provided patent services such as licensing prospect analysis, patent stability analysis, FTO analysis, and others of small molecule drugs and antibody drugs for Livzon Pharmaceutical;
- Represented Korea Investment Partners (KIP) in analyzing the prospects for patent licensing and the risk of product infringement by Maxvax Biology;
- Participated in the popularization and promotion of patent analysis in biological liquid fuel, which is the subject of China National Intellectual Property Administration;
- Participated in the research literature search in biotechnology, which is the subject of China National Intellectual Property Administration;
- Participated in Criteria for Creative Review of Specific Topics in Biotechnology, which is the subject of China National Intellectual Property Administration.

Litigations

- Represented a domestic pharmaceutical enterprise (small molecule drug), initiated the first domestic patent challenge of Class 4.1 declaration under the patent linkage system;
- Represented Livzon Pharmaceutical to deal with the patent linkage system and file a patent invalidation petition;
- Acted for Chongqing Huapont Pharmaceutical Co., Ltd. in a patent infringement lawsuit against AstraZeneca (small molecule drugs), filed a patent invalidation petition on behalf of the client, and invalidated all the opponent's patents;
- Represented Sichuan Huiyu Pharmaceutical Co., Ltd. in filing a patent invalidation petition against a pharmaceutical enterprise's patent (small molecule drugs), and invalidated all the opponent's patents;

- Represented Chia Tai Tianqing (CTTQ) in filing a patent invalidation petition against a multinational pharmaceutical enterprise's patent (small molecule drugs);
- Represented Buchang Pharma in filing a patent invalidation petition against a pharmaceutical enterprise's patent (small molecule drugs);
- Represented a medical device enterprise in filing a patent invalidation petition against a multinational company's medical device patent.

Social Positions

- Member of the Pharmaceutical Professional Committee, China Patent Protection Association
- Director of Tsinghua Health China Alumni Association
- First-term Director of the Intellectual Property Sub-committee, World Federation of Chinese Medicine Societies
- Member of the 12th Beijing Bar Association's Patent Law Committee

Education

LL.M., Tsinghua University

LL.B., China University of Political Science and Law

Visiting Scholar, University of Notre Dame

Admissions

- PRC Bar
- CNIPA Patent Agent

Language

Chinese、English